The significance of ICG-R15 in predicting hepatic toxicity in patients receiving radiotherapy for hepatocellular carcinoma

Liver International

Volumn 32, Issue 7, 2012, Pages 1165-1171

  Yoon, Hong In ^a   Koom, Woong Sub ^a   Lee, Ik Jae ^a   Jeong, Kyoungkeun ^a   Chung, Yoonsun ^a   Kim, Ja Kyung ^a   Lee, Kwan Sik ^a   Han, Kwang Hyub ^a   Seong, Jinsil ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Hepatocellular carcinoma; ICG R15; Radiation induced liver disease; Radiotherapy; Toxicity

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CISPLATIN; DOXORUBICIN; FLUOROURACIL; INDOCYANINE GREEN; IODINATED POPPYSEED OIL;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CHEMOEMBOLIZATION; FEMALE; HUMAN; HYPERBILIRUBINEMIA; INCIDENCE; INTENSITY MODULATED RADIATION THERAPY; LIVER CELL CARCINOMA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; RADIATION INJURY; RADIOFREQUENCY ABLATION; RETROSPECTIVE STUDY;

AGED; CARCINOMA, HEPATOCELLULAR; COLORING AGENTS; FEMALE; HUMANS; INDOCYANINE GREEN; LIVER DISEASES; LIVER NEOPLASMS; MALE; MIDDLE AGED; RADIATION INJURIES; RADIOTHERAPY; RETROSPECTIVE STUDIES;

EID: 84863522446     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2012.02784.x     Document Type: Article

References (27)

1. Hawkins MA, Dawson LA. Radiation therapy for hepatocellular carcinoma: from palliation to cure. Cancer 2006; 106: 1653-63.
2. Seong J, Park HC, Han KH, et al. Local radiotherapy for unresectable hepatocellular carcinoma patients who failed with transcatheter arterial chemoembolization. Int J Radiat Oncol Biol Phys 2000; 47: 1331-5.
3. Han KH, Seong J, Kim JK, et al. Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis. Cancer 2008; 113: 995-1003.
4. Seong J, Keum KC, Han KH, et al. Combined transcatheter arterial chemoembolization and local radiotherapy of unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 1999; 43: 393-7.
5. Cheng JC, Chuang VP, Cheng SH, et al. Local radiotherapy with or without transcatheter arterial chemoembolization for patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2000; 47: 435-42.
6. Pan CC, Kavanagh BD, Dawson LA, et al. Radiation-associated liver injury. Int J Radiat Oncol Biol Phys 2010; 76: S94-100.
7. Cheng JC, Wu JK, Lee PC, et al. Biologic susceptibility of hepatocellular carcinoma patients treated with radiotherapy to radiation-induced liver disease. Int J Radiat Oncol Biol Phys 2004; 60: 1502-9.
8. Xu ZY, Liang SX, Zhu J, et al. Prediction of radiation-induced liver disease by Lyman normal-tissue complication probability model in three-dimensional conformal radiation therapy for primary liver carcinoma. Int J Radiat Oncol Biol Phys 2006; 65: 189-95.
9. Ezaki T, Yamamoto K, Yamaguchi H, et al. Hepatic resection for hepatocellular carcinoma existing with liver cirrhosis. Hepatogastroenterology 2002; 49: 1363-8.
10. Scheingraber S, Richter S, Igna D, et al. Indocyanine green disappearance rate is the most useful marker for liver resection. Hepatogastroenterology 2008; 55: 1394-9.
11. Sugimoto H, Okochi O, Hirota M, et al. Early detection of liver failure after hepatectomy by indocyanine green elimination rate measured by pulse dye-densitometry. J Hepatobiliary Pancreat Surg 2006; 13: 543-8.
12. Lee CF, Yu MC, Kuo LM, et al. Using indocyanine green test to avoid post-hepatectomy liver dysfunction. Chang Gung Med J 2007; 30: 333-8.
13. Lee IJ, Seong J, Shim SJ, Han KH. Radiotherapeutic parameters predictive of liver complications induced by liver tumor radiotherapy. Int J Radiat Oncol Biol Phys 2009; 73: 154-8.
14. Hashimoto M, Watanabe G. Simultaneous measurement of effective hepatic blood flow and systemic circulation. Hepatogastroenterology 2000; 47: 1669-74.
15. Kim S, Park R, Lee KR, et al. Comparison of the indocyanine green clearance test using conventional blood sampling and finger monitoring methods. Korean J Lab Med 2003; 23: 88-91.
16. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-47.
17. Kim JS, Hahn JS, Park SY, et al. Long-term outcome after prophylactic lamivudine treatment on hepatitis B virus reactivation in non-Hodgkin's lymphoma. Yonsei Med J 2007; 48: 78-89.
18. Ingold JA, Reed GB, Kaplan HS, Bagshaw MA. Radiation hepatitis. Am J Roentgenol Radium Ther Nucl Med 1965; 93: 200-8.
19. Ogata K, Hizawa K, Yoshida M, et al. Hepatic injury following irradiation - a morphologic study. Tokushima J Exp Med 1963; 43: 240-51.
20. Reed GB Jr, Cox AJ Jr. The human liver after radiation injury. A form of veno-occlusive disease. Am J Pathol 1966; 48: 597-611.
21. Lawrence TS, Robertson JM, Anscher MS, et al. Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys 1995; 31: 1237-48.
22. Cheng JC, Wu JK, Huang CM, et al. Radiation-induced liver disease after three-dimensional conformal radiotherapy for patients with hepatocellular carcinoma: dosimetric analysis and implication. Int J Radiat Oncol Biol Phys 2002; 54: 156-62.
23. Kim TH, Kim DY, Park JW, et al. Dose-volumetric parameters predicting radiation-induced hepatic toxicity in unresectable hepatocellular carcinoma patients treated with three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 2007; 67: 225-31.
24. Gao L, Ramzan I, Baker AB. Potential use of pharmacological markers to quantitatively assess liver function during liver transplantation surgery. Anaesth Intensive Care 2000; 28: 375-85.
25. Kawasaki S, Sugiyama Y, Iga T, et al. Pharmacokinetic study on the hepatic uptake of indocyanine green in cirrhotic patients. Am J Gastroenterol 1985; 80: 801-6.
26. Cheng SH, Lin YM, Chuang VP, et al. A pilot study of three-dimensional conformal radiotherapy in unresectable hepatocellular carcinoma. J Gastroenterol Hepatol 1999; 14: 1025-33.
27. Kawashima M, Furuse J, Nishio T, et al. Phase II study of radiotherapy employing proton beam for hepatocellular carcinoma. J Clin Oncol 2005; 23: 1839-46.